Tekmira Pharmaceuticals Corporation to Present TKM-PLK1 Phase 1 Clinical Trial Results at American Association for Cancer Research
2/4/2013 9:11:14 AM
VANCOUVER, British Columbia, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has been selected as an oral presenter at the annual meeting of the American Association for Cancer Research (AACR) taking place in Washington, DC from April 6-10, 2013. "We are pleased that we have this opportunity to present Phase 1 clinical trial data from our lead oncology program, TKM-PLK1, at the AACR conference. We have completed the dose escalation portion of the trial and are continuing to enroll patients in an expansion cohort at the maximum tolerated dose. Our TKM-PLK1 program will enter a Phase 2 trial later in 2013," said Dr. Mark J. Murray, Tekmira's President and CEO.